Cetrorelix [INN] en es it fr

Cetrorelix [INN] Brand names, Cetrorelix [INN] Analogs

Cetrorelix [INN] Brand Names Mixture

  • No information avaliable

Cetrorelix [INN] Chemical_Formula

No information avaliable

Cetrorelix [INN] RX_link


Cetrorelix [INN] fda sheet

Cetrorelix_[INN] FDA

Cetrorelix [INN] msds (material safety sheet)

Cetrorelix [INN] Synthesis Reference

No information avaliable

Cetrorelix [INN] Molecular Weight

1431.06 g/mol

Cetrorelix [INN] Melting Point

No information avaliable

Cetrorelix [INN] H2O Solubility

No information avaliable

Cetrorelix [INN] State


Cetrorelix [INN] LogP

No information avaliable

Cetrorelix [INN] Dosage Forms

Powder for solution

Cetrorelix [INN] Indication

For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Cetrorelix [INN] Pharmacology

Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.

Cetrorelix [INN] Absorption

Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.

Cetrorelix [INN] side effects and Toxicity

No information avaliable

Cetrorelix [INN] Patient Information

Cetrorelix [INN] Organisms Affected

Humans and other mammals